To assess the health-related quality of life (HRQoL) of long-term, disease-free prostate cancer survivors and compare it with that of prostate cancer survivors with diabetes mellitus (DM), and a Dutch normative population, as comorbidity can have a major impact on HRQoL in cancer survivors.

PATIENTS AND METHODS

The Eindhoven Cancer Registry was used to select all men diagnosed with prostate cancer from 1994 to 1998. Questionnaires on HRQoL (Short Form 36) and prostate specific problems (University of California, Los Angeles Expanded Prostate Cancer Index) were sent to 964 patients, and 780 (81%) responded. Excluding patients with disease progression, the sample comprised 525 with prostate cancer and 65 with both prostate cancer and DM. Survivors with DM were more likely to have other comorbid conditions at the time of survey besides DM than were those without DM (74% vs 60%, P = 0.05). At 5–10 years after diagnosis, patients with DM reported worse General Health Perceptions than patients without DM or the normative population (means 52, 61 and 63; P < 0.001). Patients with DM also reported worse Vitality scores (59 vs 63; P < 0.001) than the normative population. Regression analysis indicated that DM was negatively associated with General Health Perceptions (β = −0.13; P < 0.01) and Vitality (β = −0.12; P < 0.01). Survivors with DM did not report worse urinary and bowel function or bother, nor more sexual problems than those without DM.

CONCLUSIONS

Except for general health perceptions and vitality, the HRQoL of prostate cancer survivors with or without DM was comparable to a normative population. Survivorship selection can possibly explain, in part, why patients with DM did not report worse generic or disease-specific HRQoL than those without DM, as had been expected.

REFERENCES

1 Westert GP, Satariano WA, Schellevis FG, Van Den Bos GA. Patterns of comorbidity and the use of health services in the Dutch population. Eur J Public Health 2001; 11: 365–72
10.1093/eurpub/11.4.365
CASPubMedWeb of Science®Google Scholar
2 Janssen-Heijnen ML, Houterman S, Lemmens VE et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005; 55: 231–40
10.1016/j.critrevonc.2005.04.008
PubMedWeb of Science®Google Scholar
3 Van De Poll-Franse LV, Houterman S, Janssen-Heijnen ML et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007; 120: 1986–92
10.1002/ijc.22532
CASPubMedWeb of Science®Google Scholar
4 Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071–8
10.1007/s00125-004-1415-6
CASPubMedWeb of Science®Google Scholar
5 Saito I, Inami F, Ikebe T et al. Impact of diabetes on health-related quality of life in a population study in Japan. Diabetes Res Clin Pract 2006; 73: 51–7
10.1016/j.diabres.2005.11.015
PubMedWeb of Science®Google Scholar
6 Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol 2003; 169: 1653–61
10.1097/01.ju.0000061964.49961.55
PubMedGoogle Scholar
7 Clark JA, Inui TS, Silliman RA et al. Patients’ perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003; 21: 3777–84
10.1200/JCO.2003.02.115
PubMedWeb of Science®Google Scholar
8 Wei JT, Dunn RL, Sandler HM et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557–66
PubMedWeb of Science®Google Scholar
9 Potosky AL, Legler J, Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582–92
10.1093/jnci/92.19.1582
CASPubMedWeb of Science®Google Scholar
10 Miller DC, Sanda MG, Dunn RL et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005; 23: 2772–80
10.1200/JCO.2005.07.116
PubMedWeb of Science®Google Scholar
11 Hamilton AS, Stanford JL, Gilliland FD et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 2517–26
10.1200/JCO.2001.19.9.2517
CASPubMedWeb of Science®Google Scholar
12 Rijken M, Van Kerkhof M, Dekker J, Schellevis FG. Comorbidity of chronic diseases: effects of disease pairs on physical and mental functioning. Qual Life Res 2005; 14: 45–55
10.1007/s11136-004-0616-2
PubMedWeb of Science®Google Scholar
13 Latini DM, Chan JM, Cowan JE et al. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Urology 2006; 68: 1242–7
10.1016/j.urology.2006.08.1096
PubMedWeb of Science®Google Scholar
14 Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999; 43: 475–9
10.1016/S0360-3016(98)00460-X
CASPubMedWeb of Science®Google Scholar
15 Penson DF, Latini DM, Lubeck DP et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003; 26: 1093–9
10.2337/diacare.26.4.1093
PubMedWeb of Science®Google Scholar
16 Korfage IJ, Essink-Bot ML, Borsboom GJ et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116: 291–6
10.1002/ijc.21043
CASPubMedWeb of Science®Google Scholar
17 Mols F, Van De Poll-Franse LV, Vingerhoets AJ et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer 2006; 107: 2186–96
10.1002/cncr.22231
CASPubMedWeb of Science®Google Scholar
18 Janssen-Heijnen MLG, Louwman WJ, Van De Poll-Franse LV, Coebergh JWW. Results of 50 Years Cancer Registry in the South of the Netherlands: 1955–2004 Eindhoven: Eindhoven Cancer Registry, 2005 (in Dutch)
Web of Science®Google Scholar
19 UICC. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours, 4th edn. 2nd Revision. Berlin: SpringerVerlag, 1992: 141–4
Google Scholar
20 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83
10.1016/0021-9681(87)90171-8
CASPubMedGoogle Scholar
21 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83
10.1097/00005650-199206000-00002
CASPubMedWeb of Science®Google Scholar
22 Ware JE Jr, Gandek B, Kosinski M et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1167–70
10.1016/S0895-4356(98)00108-5
PubMedWeb of Science®Google Scholar
23 Aaronson NK, Muller M, Cohen PD et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 1055–68
10.1016/S0895-4356(98)00097-3
CASPubMedWeb of Science®Google Scholar
24 Ware JE Jr. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre, 1993
Google Scholar
25 Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001; 39: 1039–47
10.1097/00005650-200110000-00002
CASPubMedWeb of Science®Google Scholar
26 Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582–92
10.1097/01.MLR.0000062554.74615.4C
PubMedWeb of Science®Google Scholar
27 Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899–905
10.1016/S0090-4295(00)00858-X
CASPubMedWeb of Science®Google Scholar
28 Korfage IJ, Essink-Bot ML, Madalinska JB et al. Measuring disease specific quality of life in localized prostate cancer: the Dutch experience. Qual Life Res 2003; 12: 459–64
10.1023/A:1023402706666
CASPubMedWeb of Science®Google Scholar
29 Dekker JM, Van Der Kraan M, Nijpels G et al. [Estimate of the number of new patients with type 2 diabetes mellitus in the Netherlands: at least 65 000 per year in the age group of 50 years and above]. Ned Tijdschr Geneeskd 2003; 147: 1419–23
CASPubMedGoogle Scholar
30 Ko GT, Chan JC, Yeung VT et al. A low socio-economic status is an additional risk factor for glucose intolerance in high risk Hong Kong Chinese. Eur J Epidemiol 2001; 17: 289–95
10.1023/A:1017935707807
CASPubMedWeb of Science®Google Scholar
31 Hu JC, Elkin EP, Pasta DJ et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171: 703–7
10.1097/01.ju.0000107964.61300.f6
PubMedWeb of Science®Google Scholar
32 Wensing M, Vingerhoets E, Grol R. Functional status, health problems, age and comorbidity in primary care patients. Qual Life Res 2001; 10: 141–8
10.1023/A:1016705615207
CASPubMedWeb of Science®Google Scholar
33 Thommasen HV, Zhang W. Impact of chronic disease on quality of life in the Bella Coola Valley. Rural Remote Health 2006; 6: 528
PubMedGoogle Scholar
34 Penson DF, Wessells H. Erectile dysfunction in diabetic patients. Diabetes Spectrum 2004; 17: 225–30
10.2337/diaspect.17.4.225
Google Scholar
35 Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know? Crit Rev Oncol Hematol 2006; 57: 165–73
10.1016/j.critrevonc.2005.06.006
PubMedWeb of Science®Google Scholar
36 Potosky AL, Davis WW, Hoffman RM et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 1358–67
10.1093/jnci/djh259
PubMedWeb of Science®Google Scholar
37 Potosky AL, Reeve BB, Clegg LX et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94: 430–7
10.1093/jnci/94.6.430
PubMedWeb of Science®Google Scholar

Citing Literature

Volume102, Issue11

December 2008

Pages 1594-1600

Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study

Abstract

OBJECTIVE

PATIENTS AND METHODS

CONCLUSIONS

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study

Abstract

OBJECTIVE

PATIENTS AND METHODS

CONCLUSIONS

REFERENCES

Citing Literature

References

Related

Information